Curegenix Inc.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors

First Posted Date
2018-04-25
Last Posted Date
2020-07-24
Lead Sponsor
Curegenix Inc.
Target Recruit Count
39
Registration Number
NCT03507998
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, China

🇨🇳

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China

CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)

First Posted Date
2016-02-05
Last Posted Date
2022-01-26
Lead Sponsor
Curegenix Inc.
Target Recruit Count
72
Registration Number
NCT02675946
Locations
🇺🇸

Edward H. Kaplan MD and Associates, Skokie, Illinois, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Memorial Care, Long Beach, California, United States

and more 22 locations
© Copyright 2024. All Rights Reserved by MedPath